Loading…
Loading…
EQUITY / NASDAQ · XNMS
Immuneering Corp. Class A Common Stock
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗4.0301 USD · -0.9803%
Observed: Oct 2, 2026, 8:21 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/02/2026 · 4.07 USD · Volume 589,006
64 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -19,000,408 USD | -14,757,894 USD | — |
| Net income | -17,270,427 USD | -14,433,881 USD | — |
| Cash and cash equivalents | 41,324,682 USD | — | — |
| Total liabilities | 11,320,301 USD | — | — |
| Total equity | 190,735,026 USD | 28,936,037 USD | +559.16% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 41,324,682 USD | — | — | 128,645,025 USD | 128,645,025 USD | 227,563,077 USD | — | — |
| Net incomeIncome statement | -17,270,427 USD | -30,731,322 USD | -13,460,895 USD | — | -56,024,898 USD | -14,964,875 USD | -44,444,888 USD | -14,433,881 USD |
| Operating profitIncome statement | -19,000,408 USD | -34,335,441 USD | — | — | -59,375,969 USD | -15,380,706 USD | -45,623,250 USD | -14,757,894 USD |
| Total assetsBalance sheet | 202,055,327 USD | — | — | 231,985,010 USD | 231,985,010 USD | 241,056,266 USD | — | — |
| Total equityBalance sheet | 190,735,026 USD | — | 206,518,171 USD | 218,483,968 USD | 218,483,968 USD | 227,976,432 USD | — | 28,936,037 USD |
| Total liabilitiesBalance sheet | 11,320,301 USD | — | — | 13,501,042 USD | 13,501,042 USD | 13,079,834 USD | — | — |
| Capital expendituresCash flow statement | — | 107,297 USD | — | — | 142,226 USD | — | 18,316 USD | — |
| Financing cash flowCash flow statement | — | 205,368 USD | — | — | 226,583,147 USD | — | 226,940,670 USD | — |
| Investing cash flowCash flow statement | — | -52,590,874 USD | — | — | -88,738,247 USD | — | -18,316 USD | — |
| Operating cash flowCash flow statement | — | -34,934,837 USD | — | — | -45,344,595 USD | — | -35,503,997 USD | — |
| Report source | Open report ↗ Published: 08/05/2026 | Open report ↗ Published: 08/05/2026 | Open report ↗ Published: 08/05/2026 | Open report ↗ Published: 08/05/2026 | Open report ↗ Published: 03/06/2026 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 11/12/2025 | Open report ↗ Published: 08/05/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.